Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973881 | 0.82 | DGAT1 (0.36) | KCNQ2DGAT1 | |
| SCHEMBL2803172 | 0.79 | MAPT (0.38) | KCNQ2 | |
| SCHEMBL4321314 | 0.79 | MEN1 (0.33) | — | |
| SCHEMBL31575340 | 0.79 | DGAT1 (0.38) | DGAT1KCNN4 | |
| SCHEMBL1969124 | 0.77 | KCNQ2 (0.33) | KCNQ2 | |
| SCHEMBL15025980 | 0.77 | KCNQ2 (0.33) | KCNQ2 | |
| SCHEMBL3629698 | 0.75 | MEN1 (0.36) | KCNQ2 | |
| SCHEMBL24403117 | 0.75 | TDP1 (0.38) | DGAT1 | |
| SCHEMBL22502088 | 0.75 | LMNA (0.36) | KCNQ2 | |
| SCHEMBL24402053 | 0.73 | DGAT1 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739390-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008451-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | SITALA BIO LTD (GB) | 2025-01-09 | — | — | WO | disclosed |
| EP-2651403-B1 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-2688891-B1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| CN-105748480-A | Methods of treatment of skin ulcers | 宾夕法尼亚大学理事会 | 2016-07-13 | — | — | CN | disclosed |
| CN-103562210-B | PI3K 110 δ are had to optionally benzo oxygen azepine * compound and using method | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-25 | — | — | CN | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2008048867-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | KCNQ2 2504/4885DGAT1 564/4885NR3C1 62/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | KCNQ2 4378/4885DGAT1 522/4885NR3C1 2569/4885 |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | KCNQ2 2525/4885DGAT1 532/4885NR3C1 59/4885 |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GPR6, CNR1, NR3C1 | KCNQ2 1614/4885DGAT1 1618/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.